{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:39:05Z","timestamp":1786541945580,"version":"build-2736575974"},"reference-count":119,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2015R1A5A2008833"],"award-info":[{"award-number":["NRF-2015R1A5A2008833"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.scib.2018.12.020","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T12:07:28Z","timestamp":1545998848000},"page":"166-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI"],"prefix":"10.1016","volume":"64","author":[{"given":"Yong","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daowen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hwa","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung","family":"Ho Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Sidney C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2018.12.020_b0005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0010","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","article-title":"\u201cEast Asian paradox\u201d: challenge for the current antiplatelet strategy of \u201cone-guideline-fits-all races\u201d in acute coronary syndrome","volume":"16","author":"Jeong","year":"2014","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.scib.2018.12.020_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005025","article-title":"A coronary heart disease prediction model: the Korean Heart Study","volume":"4","author":"Jee","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.scib.2018.12.020_b0020","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1001\/jama.291.21.2591","article-title":"Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.scib.2018.12.020_b0025","doi-asserted-by":"crossref","first-page":"784","DOI":"10.5551\/jat.19356","article-title":"Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study","volume":"21","author":"Nishimura","year":"2014","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.scib.2018.12.020_b0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/CIRCULATIONAHA.108.808311","article-title":"Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation","volume":"119","author":"Kimura","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jcin.2008.06.011","article-title":"Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents","volume":"1","author":"Park","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4070\/kcj.2017.0300","article-title":"Bioresorbable vascular scaffold Korean expert panel report","volume":"47","author":"Ahn","year":"2017","journal-title":"Korean Circ J"},{"key":"10.1016\/j.scib.2018.12.020_b0050","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0055","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.scib.2018.12.020_b0060","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.scib.2018.12.020_b0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/ha.2010.002691","volume":"3","author":"Goto","year":"2011","journal-title":"Heart Asia"},{"key":"10.1016\/j.scib.2018.12.020_b0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ahj.2008.08.031","article-title":"Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study","volume":"157","author":"Mak","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0075","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.113.001437","article-title":"Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases","volume":"127","author":"Kumar","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0080","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ahj.2015.03.015","article-title":"Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial","volume":"169","author":"Kang","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0085","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome \u2013 randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.scib.2018.12.020_b0090","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2217\/cer-2017-0074","article-title":"Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials","volume":"7","author":"Wu","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.scib.2018.12.020_b0095","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0100","first-page":"A20526","article-title":"Bleeding episode predicts the occurrence of dyspnea during ticagrelor treatment in patients with acute coronary syndrome","volume":"136","author":"Kang","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1055\/s-0038-1626697","article-title":"Third-generation P2Y12 inhibitors in East Asian acute myocardial infarction patients: a nationwide prospective multicentre study","volume":"118","author":"Kang","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.scib.2018.12.020_b0110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1253\/circj.CJ-17-0632","article-title":"Cardiovascular and bleeding risks in acute myocardial infarction newly treated with ticagrelor vs. clopidogrel in Taiwan","volume":"82","author":"Lee","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.scib.2018.12.020_b0115","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","article-title":"Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry","volume":"37","author":"Sahl\u00e9n","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0120","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijcard.2016.06.063","article-title":"Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe","volume":"220","author":"Giordana","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2018.12.020_b0130","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2018.12.020_b0135","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1253\/circj.CJ-13-1482","article-title":"Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"78","author":"Saito","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.scib.2018.12.020_b0140","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0145","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ahj.2009.01.006","article-title":"Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study","volume":"157","author":"Han","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11595930-000000000-00000","article-title":"Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study","volume":"32","author":"Li","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.scib.2018.12.020_b0155","doi-asserted-by":"crossref","first-page":"478","DOI":"10.5414\/CP202017","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers","volume":"52","author":"Teng","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.scib.2018.12.020_b0160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.5414\/CP202549","article-title":"Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes","volume":"54","author":"Li","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.scib.2018.12.020_b0165","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial","volume":"67","author":"Storey","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0170","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12928-014-0277-1","article-title":"Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease","volume":"29","author":"Hiasa","year":"2014","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.scib.2018.12.020_b0175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/09537104.2014.959913","article-title":"Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects","volume":"26","author":"Guo","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.scib.2018.12.020_b0180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2017.03.026","article-title":"The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis","volume":"238","author":"Kim","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.amjcard.2017.04.010","article-title":"Comparison of the antiplatelet effects of once and twice daily low-dose ticagrelor and clopidogrel after percutaneous coronary intervention","volume":"120","author":"Choi","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijcard.2016.04.087","article-title":"One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: a randomized, single-blind, crossover clinical study","volume":"215","author":"He","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0195","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2018.12.020_b0200","first-page":"1273","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"373","author":"Jeong","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2018.12.020_b0205","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jacc.2018.02.010","article-title":"Effect of low-dose versus standard-dose ticagrelor and clopidogrel on platelet inhibition in acute coronary syndromes","volume":"71","author":"Park","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-009-0737-1","article-title":"The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects","volume":"66","author":"Small","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.scib.2018.12.020_b0215","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.thromres.2011.11.023","article-title":"Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention","volume":"129","author":"Yokoi","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.scib.2018.12.020_b0220","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1253\/circj.CJ-14-0266","article-title":"Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention","volume":"78","author":"Isshiki","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.scib.2018.12.020_b0225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.5551\/jat.26013","article-title":"Randomized, double-blind, dose-finding, phase II study of prasugrel in Japanese patients undergoing elective percutaneous coronary intervention","volume":"22","author":"Kimura","year":"2015","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.scib.2018.12.020_b0230","article-title":"Fixed-dose (10 mg and 5 mg) versus phenotype-based prasugrel dose to match therapeutic zone with acute coronary syndrome: the A-MATCH trial","author":"Jeong","year":"2015","journal-title":"ESC Congress"},{"issue":"Suppl. F","key":"10.1016\/j.scib.2018.12.020_b0235","doi-asserted-by":"crossref","first-page":"F19","DOI":"10.1093\/eurheartj\/suw034","article-title":"Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients","volume":"18","author":"Wang","year":"2016","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.scib.2018.12.020_b0240","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijcard.2016.08.144","article-title":"Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization","volume":"223","author":"Kudaravalli","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0245","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/HPC.0000000000000030","article-title":"Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice","volume":"13","author":"Bagai","year":"2014","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0250","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0255","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2016.10.006","volume":"183","author":"Zettler","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0260","first-page":"1165","article-title":"Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge","volume":"97","author":"Liu","year":"2017","journal-title":"Natl Med J China"},{"key":"10.1016\/j.scib.2018.12.020_b0265","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamacardio.2016.1017","article-title":"Long-term Tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial","volume":"1","author":"Bonaca","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0270","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1160\/TH16-04-0340","article-title":"A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome","volume":"117","author":"Pourdjabbar","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.scib.2018.12.020_b0275","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0280","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0285","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/1570161116666180117103238","article-title":"Should antithrombotic treatment strategies in East Asians differ from caucasians?","volume":"16","author":"Bae","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.scib.2018.12.020_b0290","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.scib.2018.12.020_b0295","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","article-title":"Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin","volume":"4","author":"Jeong","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/hrt.2011.227272","article-title":"Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents","volume":"98","author":"Oh","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.scib.2018.12.020_b0305","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/CIRCGENETICS.113.000109","article-title":"CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina","volume":"6","author":"Kim","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.scib.2018.12.020_b0310","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","article-title":"CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis","volume":"7","author":"Sorich","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.scib.2018.12.020_b0315","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijcard.2017.03.015","article-title":"Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention \u2013 a multicenter study","volume":"240","author":"Li","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0320","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4244\/EIJV9I3A53","article-title":"The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation","volume":"9","author":"Liang","year":"2013","journal-title":"EuroIntervention."},{"key":"10.1016\/j.scib.2018.12.020_b0325","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.scib.2018.12.020_b0330","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0335","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijcard.2015.04.180","volume":"190","author":"Lee","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0340","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/09537104.2013.815341","article-title":"Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI","volume":"25","author":"Zhang","year":"2014","journal-title":"Platelets"},{"key":"10.1016\/j.scib.2018.12.020_b0345","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ahj.2010.10.036","article-title":"Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention","volume":"161","author":"Ko","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0350","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.thromres.2015.09.014","article-title":"No association between on-treatment platelet reactivity and bleeding events following percutaneous coronary intervention and antiplatelet therapy: a post hoc analysis","volume":"136","author":"Nishikawa","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.scib.2018.12.020_b0355","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","volume":"57","author":"Suh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0360","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jcin.2011.12.009","article-title":"Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction","volume":"5","author":"Ahn","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0365","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.amjcard.2011.07.012","article-title":"Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study)","volume":"108","author":"Park","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0370","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ijcard.2012.04.154","article-title":"High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting","volume":"167","author":"Jin","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0375","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41598-017-18134-y","article-title":"Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study","volume":"8","author":"Joo","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.scib.2018.12.020_b0380","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.scib.2018.12.020_b0385","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jcin.2010.05.007","volume":"3","author":"Jeong","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0390","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/09537104.2015.1095875","article-title":"Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction","volume":"27","author":"Lee","year":"2016","journal-title":"Platelets"},{"key":"10.1016\/j.scib.2018.12.020_b0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jjcc.2015.07.019","article-title":"Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study","volume":"68","author":"Ogawa","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0400","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/AC.71.3.3152091","article-title":"High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial","volume":"71","author":"Zhang","year":"2016","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0405","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0410","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0415","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1161\/CIRCULATIONAHA.113.007524","article-title":"High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study","volume":"129","author":"Montalescot","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0420","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0425","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1253\/circj.CJ-15-0270","article-title":"Comparison of prasugrel and ticagrelor antiplatelet effects in Korean patients presenting with ST-segment elevation myocardial infarction","volume":"79","author":"Lee","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.scib.2018.12.020_b0430","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3904\/kjim.2015.30.5.620","article-title":"A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome","volume":"30","author":"Lee","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.scib.2018.12.020_b0435","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4070\/kcj.2013.43.8.541","article-title":"Genotype- and phenotype-directed personalization of antiplatelet treatment in patients with non-ST elevation acute coronary syndromes undergoing coronary stenting","volume":"43","author":"Ahn","year":"2013","journal-title":"Korean Circ J"},{"key":"10.1016\/j.scib.2018.12.020_b0440","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0445","first-page":"8","article-title":"Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions","author":"Koskinas","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0450","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0735-1097(16)31841-1","article-title":"Low-dose aspirin for the primary prevention of cardiovascular events: a systemic metaanalysis comparing East Asian versus Western population","volume":"67","author":"Jeong","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0455","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1160\/TH11-04-0214","article-title":"Current antithrombotic treatment in East Asia: some perspectives on anticoagulation and antiplatelet therapy","volume":"107","author":"Ma","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.scib.2018.12.020_b0460","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131558","article-title":"PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: systematic review and meta-analysis","volume":"10","author":"Mo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.scib.2018.12.020_b0470","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ajg.2011.385","article-title":"Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction","volume":"107","author":"Ng","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.scib.2018.12.020_b0475","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000141264","article-title":"Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy","volume":"77","author":"Ng","year":"2008","journal-title":"Digestion"},{"key":"10.1016\/j.scib.2018.12.020_b0480","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.scib.2018.12.020_b0485","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.scib.2018.12.020_b0490","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2018.12.020_b0495","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0500","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jacc.2015.03.591","article-title":"TCTAP A-095 impact of proton pump inhibitor on one-year clinical outcomes in patients underwent percutaneous coronary intervention according to dual versus triple antiplatelet agents","volume":"65","author":"Park","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0505","first-page":"556","article-title":"Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry","volume":"80","author":"Aihara","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0510","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.amjcard.2010.01.348","article-title":"Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention","volume":"105","author":"Huang","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0515","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijcard.2014.09.036","article-title":"Proton pump inhibitor use represents an independent risk factor for myocardial infarction","volume":"177","author":"Shih","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0520","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jtcvs.2016.07.044","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"152","author":"Levine","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.scib.2018.12.020_b0525","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0530","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.scib.2018.12.020_b0535","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0540","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0545","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.scib.2018.12.020_b0550","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0555","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.scib.2018.12.020_b0560","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.scib.2018.12.020_b0565","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11684-017-0502-2","article-title":"Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients","volume":"11","author":"Sun","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.scib.2018.12.020_b0570","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2018.12.020_b0575","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0038-1676545","article-title":"Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs","volume":"119","author":"Kang","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.scib.2018.12.020_b0610","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s13063-015-0925-5","article-title":"Harmonizing optimal strategy for treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial","volume":"16","author":"Lee","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.scib.2018.12.020_b0580","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.scib.2018.12.020_b0590","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2018.12.020_b0605","first-page":"396","article-title":"Rivaroxaban in stable cardiovascular disease","volume":"378","author":"Jeong","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927318306029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927318306029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:37:15Z","timestamp":1761867435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927318306029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2095927318306029"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2018.12.020","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2018.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Science China Press. Published by Elsevier B.V. and Science China Press. All rights reserved.","name":"copyright","label":"Copyright"}]}}